Speakers
Speakers by Track
Plenary
Preclinical and Translational Immuno-Oncology
Immunomodulatory Approaches
CARs, TILs, TCRs
Biomarkers for Immuno-Oncology
Combination Immunotherapy
Bispecific Antibody Design and Applications
Plenary
Stanley Riddell, MD, Scientific Director, Clinical Research, Fred Hutchinson Cancer Research Center; Professor, University of Washington School of Medicine
Roy D. Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Sharpe & Dohme
Preclinical and Translational Immuno-Oncology
Carlo Boutton, PhD, Head Nanobody Explorative Technologies, Discovery, Ablynx - Sanofi
Catarina Brito, PhD, Lab Head, Advanced Cell Models Lab, Animal Cell Technology Unit, iBET Catarina
Sara Colombetti, PhD, Global Head of Oncology Discovery Pharmacology, Pharma Research and Early Development (pRED), Roche Innovation Center Zurich
Lindy Durrant, PhD, Professor of Cancer immunotherapy, University of Nottingham; CSO, Scancell Ltd
Andrew Exley, PhD, Medical Assessor, Biologicals and Biotechnology Unit, MHRA
Denise Faustman, MD, PhD, Director of Immunobiology, Medicine, Harvard Medical School/Massachusetts General Hospital
Melanie Glossop, BSc, CChem, FRSC, Head of Chemistry, Centauri Therapeutics
Elizabeth Hardaker, PhD, Associate Director & Head, Oncology In Vivo Pharmacology Group, AstraZeneca
Russell W. Jenkins, MD, PhD, Faculty, Harvard Medical School; Assistant Physician, Massachusetts General Hospital
Tony Ng, FMEDSCI, MB, ChB, MRCP, FRCPath, PhD, Head of School of Cancer and Pharmaceutical Sciences, King’s College London, CRUK City of London Centre Executive Member, Richard Dimbleby Chair of Cancer Research, Group Leader, KCL Breast Cancer Now
Research Unit, Director, KCL and UCL Comprehensive Cancer Imaging Centre, Chair of Molecular Oncology, UCL Cancer Institute
Stefan Ries, PhD, Global Head of External Innovation, Oncology, pRED Oncology, Roche Pharma, Roche Innovation Center Munich
Armin Sepp, PhD, Scientific Leader and GSK Fellow, IVIVT DMPK Modelling, GlaxoSmithKline
Eric Smith, PhD, Senior Director, Bispecific Antibodies, Regeneron Pharmaceuticals
Elena Spanjaard, PhD, Global Head of Regulatory Affairs, Celyad
Immunomodulatory Approaches
Stephen A. Beers, PhD, Professor of Immunology and Immunotherapy, Centre for Cancer Immunology, Cancer Sciences Unit, University of Southampton
Laura Codarri Deak, PhD, Principal Scientist, Cancer Immunotherapy, Roche Pharmaceutical Research and Early Development
Mark Cragg, PhD, Professor, Experimental Cancer Biology, Antibody & Vaccine Group, Cancer Sciences Unit, University of Southampton
Tanja de Gruijl, PhD, Professor and Chair of Translational Tumor Immunology, Medical Oncology, VU University Medical Center Amsterdam
Jane Grogan, PhD, Head Adaptive Tumor Immunity & Principal Scientist, Cancer Immunology, Genentech
Sophia N. Karagiannis, BA, MS, PhD, Reader, Translational Cancer Immunology, St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London
Roman Kischel, MD, Director Research & Early Development Lead, Amgen Research Munich GmbH
Manfred Kraus, PhD, Director In Vivo Pharmacology & Oncology, In Vivo Pharmacology & Oncology, Pfizer
James Legg, PhD, Senior Vice President, Research, Crescendo Biologics
Jeanette Leusen, PhD, Associate Professor and Head Immunotherapy Group, Translational Immunology, University Medical Centre Utrecht
Michelle Morrow, PhD, Vice President, Preclinical Translational Pharmacology, F-star
Dario Neri, PhD, Professor, Biomacromolecules, Chemistry and Applied Biosciences, ETH Zürich
Karin Enell Smith, PhD, Senior Scientist, Preclinical Development, Alligator Bioscience AB
Hans van der Vliet, MD, PhD, CSO, LAVA therapeutics; Medical Oncologist, Amsterdam UMC
CARs, TILs, TCRs
Hinrich Abken, PhD, Professor, Chair Gene-Immunotherapy, Regensburg Center for Interventional Immunology, University Regensburg
James Arnold, PhD, Professor, Cancer Cell Biology and Imaging, Kings College London
Renier Brentjens, MD, PhD, Director, Cellular Therapeutics Center, Memorial Sloan-Kettering Cancer Center; Professor, Pharmacology, Weill Cornell Graduate School of Medical Sciences
Jo Brewer, PhD, Vice President, Allogeneic Research, AdaptImmune
George Coukos, Full Professor and Director, Oncology, Centre Hospitalier Universitaire Vaudois (CHUV) and University of Lausanne (UNIL); Director, Lausanne Branch, Ludwig Institute of Cancer Research Chief, Service of Immuno-Oncology, CHUV
Phil Darcy, PhD, Professor, NHMRC Principal Research Fellow, Laboratory Head Cancer Immunotherapy, Peter MacCallum Cancer Centre
Reno Debets, PhD, Associate Professor, Laboratory of Tumor Immunology, PI, Medical Oncology, Erasmus MC-Cancer Institute
David E Gilham, PhD, Vice President, R&D, Celyad
Weidong Han, PhD, Professor, Biotherapeutic, Chinese PLA General Hospital, Beijing, China
Robert Hawkins, MB BS, MRCP, PhD, FRCP, CEO, Immetacyte Ltd.; Honorary Professor, Medical Oncology, University of Manchester
Daniel Irimia, MD, PhD, Associate Professor, Surgery, Harvard Medical School, Massachusetts General Hospital, USA
Michael Klichinsky, PharmD, PhD, Co-Founder, Vice President, Discovery, Carisma Therapeutics
Mark Lowdell, PhD, Director, Centre for Cell, Gene & Tissue Therapeutics, RFH; Professor, Cell & Tissue Therapy, University College London
John Maher, FRCPath, PhD, Consultant & Senior Lecturer, Immunology, Cancer Studies, King’s College London
Andrew Sewell, PhD, Distinguished Research Professor and Wellcome Trust Senior Investigator, Infection & Immunity, Cardiff University School of Medicine
Biomarkers for Immuno-Oncology
Edith Borcoman, MD, Medical Oncologist, Institut Curie, Paris
Tricia Cottrell, PhD, Assistant Professor, Pathology and Molecular Medicine, Queens University
Roxana Dronca, MD, Associate Professor of Oncology, Consultant and Chair, Division of Hematology-Oncology, Mayo Clinic
Darius M. Dziuda, PhD, Professor, Mathematical Sciences, Central Connecticut State University
Kenneth Emancipator, MD, Executive Medical Director, Companion Diagnostics and Translational Medicine, Merck Sharp and Dohme (MSD)
Bruno Gomes, DVM, PhD, Head of Oncology Biomarkers, Early Clinical Development Oncology, Roche Pharma Research and Early Development
Felix Faber, CEO and Founder, MindPeak GmbH
Lukas Heukamp, MB, PhD, Director Molecular Pathology, Molecular Pathology, Institut für Hämatopathologie Hamburg
Sheeba Irshad, MD, PhD, Senior Clinical Lecturer, Cancer and Pharmaceutical Sciences, Kings College London
Eugean Jiwanmall, MPH, MBA, Senior Research Analyst, Technology Evaluation & Medical Policy, INDEPENDENCE BLUE CROSS
Daniel R. Karlin, MD, MA, CEO, HealthMode, Inc.
Benedikt Kessler, PhD, Professor of Biochemistry and Life Science Mass Spectrometry, Nuffield Department of Medicine, University of Oxford
Graham Pockley, PhD, CEO, multimmune GmbH; Professor of Immunobiology, John van Geest Cancer Research Centre, Nottingham Trent University
Camelia Quek, PhD, Senior Scientist Postdoctoral Scientist, Cancer Immunotherapy & Biomarkers, Melanoma Institute Australia
Wouter Scheper, PhD, Senior postdoc, Molecular Oncology and Immunology, Netherlands Cancer Institute
Jo Van Ginderachter, PhD, VIB Group Leader, Tumor-host interactions, Lab of Cellular and Molecular Immunology, VIB-Vrije Universiteit Brussel
Combination Immunotherapy
John Bell Ottawa, PhD, Senior Scientist, Innovative Cancer Therapeutics, Ottawa Hospital Research Institute
Ivan Diaz Padilla, MD, PhD, Executive Medical Director, Global Clinical Development Lead ; DNA-damage repair program, Oncology Global Clinical Development, Ares Trading, S.A. [Merck Group]
Jakob Dupont, MD, MA, Chief Medical Officer, Gossamer Bio
Tina J. Hieken, MD, Associate Professor of Surgery, Mayo Clinic
Gordon J. Freeman, PhD, Professor of Medicine, Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School
Franco Marincola, PhD, Chief Scientific Officer, Refuge Biotechnologies
John Maher, MD, Consultant, Immunology, Kings College London
Philipp Müller, PhD, Senior Principal Scientist, Cancer Immunology & Immune Modulation, Boehringer Ingelheim Pharma GmbH & Co. KG
Karoline Schjetne, PhD, Vice President Scientific Affairs, Vaccibody
Dimitris Skokos, PhD, Director, Immunity & Inflammation, Regeneron Pharmaceuticals
Paul Song, MD, Chief Medical Officer, Translation Medicine, NKMax America
Bispecific Antibody Design and Applications
Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart
Mark Throsby, PhD, CSO, Merus NV
Paul Widboom, PhD, Associate Director, Antibody Discovery, Adimab LLC
Marlon J. Hinner, PhD, Principal Scientist, Group Leader Phage Display, Large Molecule Research, Roche Pharma Research and Early Development (pRED), Roche Innovation Center Munich
Stefano Majocchi, PhD, Therapeutic Program Lead, Light Chain Bioscience
Matthew J. Bernett, PhD, Associate Director, Protein & Antibody Engineering, Xencor, Inc.
Maria Karasarides, PhD, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals
John Babcook, PhD, Senior Vice President, Discovery Research, Zymeworks
Julian Andreev, PhD, Research Fellow, Oncology & Angiogensis, Regeneron Pharmaceuticals, Inc.
Jamie Baker, PhD, Chemistry, University College London
Dimitris Skokos, PhD, Associate Director, Immunology & Inflammation, Regeneron Pharmaceuticals
James Legg, PhD, Senior Vice President, Research, Crescendo Biologics
Anne Mansson-Kvarnhammar, PhD, Senior Scientist, Alligator Bioscience AB
Mathieu Cinier, PhD, Scientific Director, Affilogic